Matinas BioPharma MTNB 深 沪
已收盘 10-30 16:00:00 美东时间
1.51
-0.390
-20.53%
华盛通- 最 高1.91
- 今 开1.87
- 成交量 8.30万股
- 最 低 1.505
- 昨 收 1.90
- 总市值 147.91万
- 52周最高 19.95
- 市盈率 静 --
- 换手率 8.47%
- 52周最低 1.4693
- 委 比 0.00%
- 总股本 97.95万
- 历史最高 2962.50
- 量 比 4.12
- 振 幅 21.32%
- 历史最低 1.4693
- 每 手 1
- 风险率 4.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Matinas BioPharma Board Approves 1-For-15 Reverse Stock Split Effective September 28, 2026
On June 23, 2025, at the 2025 annual meeting of stockholders of Matinas BioPharma Holdings, Inc. (the "Company"), the stockholders approved the authorization of the Board of Directors (the "Board"), in its sole and absolute discretion and without further stockholder approval, to effect up to two rev...
09-17 05:25
Matinas BioPharma gets 2027 window to restore NYSE American listing compliance
Matinas BioPharma Holdings (MTNB) announced on Friday that it received a non-compliant notice from NYSE American for falling below its stockholders’ equity requirement. The company had $1.8M in stockh...
09-05 05:16
Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards
Matinas BioPharma Holdings, Inc. received a notice from NYSE American regarding noncompliance with continued listing standards due to insufficient stockholders’ equity and consecutive losses. The company has submitted a compliance plan with a deadline of October 2, 2027. Its shares remain listed on NYSE American but are marked as noncompliant. The company focuses on developing therapies using lipid nanocrystal technology, including MAT2203, a pot...
09-04 21:00
BTIG Terminates Sales Agreement With Matinas BioPharma, Effective Immediately On July 23; Incurs No Termination Penalties Or Expenses From Sales Agreement Termination
As previously disclosed, on July 2, 2020, Matinas BioPharma Holdings, Inc. (the "Company") entered into an At-The-Market Sales Agreement (the "Sales Agreement") with BTIG, LLC ("BTIG"), pursuant to which the Company could offer and sell shares of its common stock, par value $0.0001 per share ("Commo...
07-25 05:11
Matinas Biopharma Holdings shares are trading lower. The company announced it entered into a definitive purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc., including MAT220 to Azurity Pharmaceuticals.
Matinas Biopharma Holdings shares are trading lower. The company announced it entered into a definitive purchase agreement to sell Matinas BioPharma Nanotechnologies, Inc., including MAT220 to Azurity Pharmaceuticals.
07-13 20:48
Matinas BioPharma Announces Strategic Business Combination with GH Power to Create Publicly Traded, Advanced Clean Energy and Green Hydrogen Company; Signs Definitive Agreement to Sell LNC Platform Technology and Lead Product Candidate MAT2203 to Azurity Pharmaceuticals
Matinas BioPharma Holdings, Inc. has entered into a definitive business combination agreement with GH Power Inc. to create a publicly traded clean energy company focused on modular carbon-free energy, green hydrogen, and critical materials. The transaction is expected to provide a public market platform to accelerate commercialization and growth across North America and Europe. Additionally, Matinas has agreed to sell its subsidiary, Matinas BioP...
07-13 12:00
Matinas BioPharma Granted NYSE American Compliance Extension
The latest announcement is out from Matinas BioPharma ( ($MTNB) ). On June 24, ...
06-27 05:52
